Details of the Drug Combination

General Information of Drug Combination (ID: DCE18U0)

• Drug Combination Name: Vismodegib + BIO-300
• Indication: Malignant melanoma; Status: Investigative [1]
• Component Drugs:
  Vismodegib (DM5IXKQ): Small molecular drug
  BIO-300 (DMJ7NVI): N.A.
• High-throughput Screening Result:
  Testing Cell Line: UACC62
  Zero Interaction Potency (ZIP) Score: 10.37
  Bliss Independence Score: 10.91
  Loewe Additivity Score: 8.62
  LHighest Single Agent (HSA) Score: 10.79

Molecular Interaction Atlas of This Drug Combination

Indication(s) of Vismodegib

Disease Entry	ICD 11	Status	REF
Basal cell carcinoma	2C32	Approved	[2]
Primitive neuroectodermal tumour medulloblastoma	2A00.11	Phase 2	[3]

Vismodegib Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Smoothened homolog (SMO)	TT8J1S3	SMO_HUMAN	Modulator	[6]

Vismodegib Interacts with 2 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[7]
Cytochrome P450 2C9 (CYP2C9)	DE5IED8	CP2C9_HUMAN	Metabolism	[7]

Vismodegib Interacts with 13 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A)	OTBPCU2O	TR10A_HUMAN	Increases Expression	[8]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B)	OTA1CPBV	TR10B_HUMAN	Increases Expression	[8]
Zinc finger protein GLI1 (GLI1)	OT1BTAJO	GLI1_HUMAN	Decreases Expression	[8]
Zinc finger protein GLI2 (GLI2)	OTIRV97L	GLI2_HUMAN	Decreases Expression	[8]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Decreases Expression	[8]
Platelet-derived growth factor receptor alpha (PDGFRA)	OTDJXUCN	PGFRA_HUMAN	Decreases Expression	[8]
Tumor necrosis factor receptor superfamily member 6 (FAS)	OTP9XG86	TNR6_HUMAN	Increases Expression	[8]
Caspase-3 (CASP3)	OTIJRBE7	CASP3_HUMAN	Increases Cleavage	[8]
Protein patched homolog 1 (PTCH1)	OTMG07H5	PTC1_HUMAN	Decreases Expression	[8]
Protein smoothened (SMO)	OTXXE208	SMO_HUMAN	Decreases Expression	[8]
Protein patched homolog 2 (PTCH2)	OTOQ0K9V	PTC2_HUMAN	Decreases Expression	[8]
Suppressor of fused homolog (SUFU)	OT0IRYG1	SUFU_HUMAN	Decreases Response To Substance	[9]
N-myc proto-oncogene protein (MYCN)	OTWD33K1	MYCN_HUMAN	Decreases Response To Substance	[9]

Indication(s) of BIO-300

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[4]
Rheumatoid arthritis	FA20	Phase 1	[5]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Carcinoma	DCM7B0F	RXF 393	Investigative	[10]
Carcinoma	DCYR7W6	MCF7	Investigative	[10]
Colon carcinoma	DCABYCK	KM12	Investigative	[10]
Invasive ductal carcinoma	DC8LSL0	BT-549	Investigative	[10]
Invasive ductal carcinoma	DC0WA3Y	T-47D	Investigative	[10]
Adenocarcinoma	DC6K8PZ	DU-145	Investigative	[1]
Adenocarcinoma	DCDRGWC	OVCAR3	Investigative	[1]
Adenocarcinoma	DCFQ00K	A549	Investigative	[1]
Adenocarcinoma	DCKP4VP	NCIH23	Investigative	[1]
Adenocarcinoma	DCUZR7D	HCT116	Investigative	[1]
Adenocarcinoma	DCSRZBV	HCC-2998	Investigative	[1]
Adenocarcinoma	DCFAOYW	HCT-15	Investigative	[1]
Adenocarcinoma	DCZFKNE	HT29	Investigative	[1]
Adult T acute lymphoblastic leukemia	DCPVFKO	MOLT-4	Investigative	[1]
Astrocytoma	DCY8O52	U251	Investigative	[1]
Chronic myelogenous leukemia	DCK1XRD	K-562	Investigative	[1]
Clear cell renal cell carcinoma	DCL2OXC	786-0	Investigative	[1]
Clear cell renal cell carcinoma	DCJZYZJ	A498	Investigative	[1]
Clear cell renal cell carcinoma	DCLFOVV	TK-10	Investigative	[1]
Glioma	DC0YUE8	SF-295	Investigative	[1]
Glioma	DCAMVES	SF-539	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCNJ83Z	OVCAR-8	Investigative	[1]
High grade ovarian serous adenocarcinoma	DCWFIGC	OVCAR-5	Investigative	[1]
Lung adenocarcinoma	DCZ8WGE	EKVX	Investigative	[1]
Lung adenocarcinoma	DCGAL8F	MDA-MB-231	Investigative	[1]
Lung adenocarcinoma	DCMAU9X	NCI-H522	Investigative	[1]
Minimally invasive lung adenocarcinoma	DCG6N3M	NCI-H322M	Investigative	[1]
Mixed endometrioid and clear cell carcinoma	DCY1OX5	IGROV1	Investigative	[1]
Non-small cell lung carcinoma	DCETPJ9	HOP-92	Investigative	[1]
Prostate carcinoma	DC4TFTA	PC-3	Investigative	[1]

References

• [1] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6975).
• [3] A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015 Jul;73(1):99-105.e1.
• [4] Clinical pipeline report, company report or official report of Humanetics.
• [5] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [6] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [7] The dawn of hedgehog inhibitors: Vismodegib. J Pharmacol Pharmacother. 2013 Jan;4(1):4-7.
• [8] Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS One. 2011;6(11):e27306. doi: 10.1371/journal.pone.0027306. Epub 2011 Nov 8.
• [9] Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med. 2014 Jul;20(7):732-40. doi: 10.1038/nm.3613. Epub 2014 Jun 29.
• [10] Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.